Another important drawback is the absence of a control group, but we must be aware that due to the nature of the disease, patients with PAD represent an older population with a number of comorbidities, so it is almost impossible to form a control group that is free of associated diseases that affect the number of CD34+ cells in the peripheral blood. This evidence concerns the gene CD34 and peripheral arterial disease.